Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 10/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12037932 | 0.92 | METAP2 (0.40) | METAP2PDE10AFFAR2 | |
| SCHEMBL12067545 | 0.82 | METAP2 (0.42) | METAP2PDE10AKDM4EALDH1A1HPGD | |
| SCHEMBL2544609 | 0.81 | METAP2 (0.43) | METAP2PDE10A | |
| SCHEMBL20460356 | 0.75 | PIK3CD (0.40) | — | |
| SCHEMBL12022034 | 0.72 | METAP2 (0.42) | METAP2IRAK4 | |
| SCHEMBL18596716 | 0.70 | METAP2 (0.42) | METAP2IRAK4 | |
| SCHEMBL2544610 | 0.69 | METAP2 (0.41) | METAP2PDE10A | |
| SCHEMBL12022033 | 0.69 | METAP2 (0.39) | METAP2KDM4EALDH1A1L3MBTL1IRAK4 | |
| SCHEMBL2539733 | 0.66 | METAP2 (0.61) | METAP2KDM4EALDH1A1HPGDFFAR2 | |
| SCHEMBL2539728 | 0.66 | METAP2 (0.61) | METAP2KDM4EALDH1A1HPGDFFAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294952-A1 | Optimized Drug Conjugates | SynDevRX (US) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294952-A1 | Optimized Drug Conjugates | ABCB1, ABCG2, UGT1A3 | METAP2 2243/4885PDE10A 4100/4885KDM4E 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.